Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

A compound represented by formula (I) or formula (II) has a pest control effect. (In the formulae, Q.sup.1 represents a pyrazine ring or the like; G.sup.1 represents a nitrogen atom or a carbon atom; X.sup.1 represents an alkyl group or the like; m represents the number of X.sup.1 moieties; A represents an oxygen atom or the like; Y represents a single bond or the like; Q.sup.2 represents a benzene ring or the like; X.sup.2 represents an alkyl group, an aryl group or the like; X.sup.3 represents a halogeno group or the like; n represents the number of X.sup.3 moieties; Z.sup.q- represents a counter ion; and q represents 1 or 2.)

##STR00001##

A compound represented by formula (I) or formula (II) has a pest control effect. (In the formulae, Q.sup.1 represents a pyrazine ring or the like; G.sup.1 represents a nitrogen atom or a carbon atom; X.sup.1 represents an alkyl group or the like; m represents the number of X.sup.1 moieties; A represents an oxygen atom or the like; Y represents a single bond or the like; Q.sup.2 represents a benzene ring or the like; X.sup.2 represents an alkyl group, an aryl group or the like; X.sup.3 represents a halogeno group or the like; n represents the number of X.sup.3 moieties; Z.sup.q- represents a counter ion; and q represents 1 or 2.)

##STR00001##

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: ##STR00001## Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: ##STR00001## Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.